Reinterpretation of 2017 Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease_West China Medical Journal

Authors：

 WEN Fuqiang

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

WEN Fuqiang, Email: wenfuqiang@126.com

Keywords：

Chronic obstructive pulmonary disease; Diagnosis; Management

DOI：

10.7507/1002-0179.201710025

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease is produced based on important studies published in last five years and published online. So far it is the most influential evidence-based strategy for the diagnosis, treatment and prevention of chronic obstructive pulmonary disease to guide clinical professionals.

Citation： WEN Fuqiang. Reinterpretation of 2017 Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. West China Medical Journal, 2018, 33(1): 23-27. doi: 10.7507/1002-0179.201710025 Copy

1.	文富强. GOLD 2017 更新与中国慢性阻塞性肺疾病诊治实践. 中华医学杂志, 2017, 97(38): 2967-2971.
2.	申永春, 文富强. 2016 年慢性阻塞性肺疾病全球创议更新解读. 中国实用内科杂志, 2016, 36(5): 382-384.
3.	The Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 global strategy for the diagnosis, management and prevention of COPD. (2017-02-10)[2017-10-10]. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
4.	郑劲平. 慢性阻塞性肺疾病的肺功能检查中 FEV₁ 与 IC 的临床应用. 中国实用内科杂志, 2014(增刊 1): 1-4.
5.	US Preventive Services Task Force (USPSTF), Siu AL, Bibbins-Domingo K, et al. Screening for chronic obstructive pulmonary disease: US preventive services task force recommendation statement. JAMA, 2016, 315(13): 1372-1377.
6.	Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med, 2013, 1(1): 43-50.
7.	Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med, 2015, 192(9): 1068-1079.
8.	Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med, 2016, 374(23): 2222-2234.
9.	Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β₂-agonist therapy for chronic obstructione pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet, 2016, 388(10048): 963-973.
10.	Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by COPD patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med, 2017, 195(10): 1333-1343.
11.	Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016, 4(5): 390-398.
12.	Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med, 2015, 3(6): 435-442.
13.	Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax, 2016, 71(2): 118-125.
14.	Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting β₂-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med, 2016, 194(5): 559-567.
15.	Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, 365(8): 689-698.
16.	Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med, 2012, 186(1): 48-55.
17.	Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA, 2013, 309(21): 2223-2231.
18.	Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents, 2001, 18(6): 503-512.
19.	The Global Initiative for Chronic Obstructive Lung Disease. 2018 global strategy for the diagnosis, management and prevention of COPD. (2017-11-19)[2017-12-19]. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.

1. 文富强. GOLD 2017 更新与中国慢性阻塞性肺疾病诊治实践. 中华医学杂志, 2017, 97(38): 2967-2971.
2. 申永春, 文富强. 2016 年慢性阻塞性肺疾病全球创议更新解读. 中国实用内科杂志, 2016, 36(5): 382-384.
3. The Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 global strategy for the diagnosis, management and prevention of COPD. (2017-02-10)[2017-10-10]. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
4. 郑劲平. 慢性阻塞性肺疾病的肺功能检查中 FEV₁ 与 IC 的临床应用. 中国实用内科杂志, 2014(增刊 1): 1-4.
5. US Preventive Services Task Force (USPSTF), Siu AL, Bibbins-Domingo K, et al. Screening for chronic obstructive pulmonary disease: US preventive services task force recommendation statement. JAMA, 2016, 315(13): 1372-1377.
6. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med, 2013, 1(1): 43-50.
7. Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med, 2015, 192(9): 1068-1079.
8. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med, 2016, 374(23): 2222-2234.
9. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β₂-agonist therapy for chronic obstructione pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet, 2016, 388(10048): 963-973.
10. Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by COPD patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med, 2017, 195(10): 1333-1343.
11. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016, 4(5): 390-398.
12. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med, 2015, 3(6): 435-442.
13. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax, 2016, 71(2): 118-125.
14. Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting β₂-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med, 2016, 194(5): 559-567.
15. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, 365(8): 689-698.
16. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med, 2012, 186(1): 48-55.
17. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA, 2013, 309(21): 2223-2231.
18. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents, 2001, 18(6): 503-512.
19. The Global Initiative for Chronic Obstructive Lung Disease. 2018 global strategy for the diagnosis, management and prevention of COPD. (2017-11-19)[2017-12-19]. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.

West China Medical Journal

Reinterpretation of 2017 Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content